Novo Nordisk’s Wegovy Supply Delays: FDA Uncovers Catalent Factory Lapses Violating Safety Regulations
The production facility that fills the self-injection pens for the rapidly-growing weight-loss medication Wegovy from Novo Nordisk A/S (NYSE: NVO) has been found to have persistently violated U.S.